Journal ArticleDOI
Osimertinib compared to docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small cell lung cancer.
TLDR
Osimertinib, an oral irreversible EGFR tyrosine kinase inhibitor, had promising results in patients with EGFR T790M resistance mutation of non-small-cell lung cancer (NSCLC).Abstract:
9017Background: Osimertinib, an oral irreversible EGFR tyrosine kinase inhibitor, had promising results in patients with EGFR T790M resistance mutation of non-small-cell lung cancer (NSCLC). This s...read more
Citations
More filters
Journal ArticleDOI
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Louis Fehrenbacher,Joachim von Pawel,Keunchil Park,Achim Rittmeyer,David R. Gandara,Santiago Ponce Aix,Ji Youn Han,Shirish M. Gadgeel,Toyoaki Hida,Diego Cortinovis,Manuel Cobo,Dariusz M. Kowalski,Filippo de Marinis,M. Gandhi,Bradford Danner,C. Matheny,Marcin Kowanetz,Pei He,Federico Felizzi,Hina Patel,Alan Sandler,Marcus Ballinger,Fabrice Barlesi +22 more
TL;DR: The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel and continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.
Journal ArticleDOI
Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
TL;DR: Generally, osimertinib is a favorable treatment option for previously treated T790M mutation‐positive advanced NSCLC as well as a preferable therapy for untreated EGFR mutation‐ positive advancedNSCLC.
Journal ArticleDOI
Progress in the Management of Advanced Thoracic Malignancies in 2017.
TL;DR: The characterization of biomarkers predictive of sensitivity or resistance to immunotherapy and the identification of the optimal therapeutic combinations and treatment sequence represent the toughest upcoming challenges in the domain of thoracic oncology.
Related Papers (5)
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience:
Ivana Sullivan,David Planchard +1 more